COMBINING IPILIMUMAB, DEGARELIX, AND RADICAL PROSTATECTOMY IN MEN WITH NEWLY DIAGNOSED METASTATIC CASTRATION SENSITIVE PROSTATE CANCER OR IPILIMUMAB AND DEGARELIX IN MEN WITH BIOCHEMICALLY RECURRENT CASTRATION SENSITIVE PROSTATE CANCER AFTER RADICAL PROSTATECTOMY: